GLUT1 Biomarker Stratification for Hematologic Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prognostic factors for hematologic disorders like multiple myeloma (MM) are not fully understood, and there is a need for biomarkers to refine prognosis and determine response to therapy, particularly for conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM).
Innovation Solution
The proportion of plasma cells, lymphocytes, or blasts expressing GLUT1 is used as a biomarker to stratify prognosis and predict response to BCL-2 family protein modulators by determining and comparing this proportion with reference values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current prognostic factors are used for hematologic disorders, then existing treatment decisions can be made, but prognosis refinement and personalized treatment strategies are limited
Solution Approach 1:
The patent changes the parameter used for prognosis assessment from conventional factors (age, disease stage, cytogenetics) to GLUT1 expression proportion in plasma cells. This parameter change enables more precise prognosis stratification and personalized treatment decisions, as GLUT1 expression level directly correlates with disease progression risk and therapy response.
Solution Approach 2:
The patent replaces the conventional mechanical/system-based prognostic assessment (relying on anatomical and clinical parameters) with a molecular/biomarker-based system (GLUT1 expression). This substitution provides more accurate and versatile prognosis prediction, enabling better personalized treatment strategies.
2Adaptability or versatility
If more biomarkers are sought to refine prognosis, then treatment personalization improves, but complexity of assessment increases
Solution Approach 1:
The patent extracts and focuses on a single key biomarker (GLUT1 expression proportion) from the complex landscape of potential markers. By isolating this specific parameter, the patent achieves prognosis refinement without requiring a complex multi-marker assessment system, thus maintaining simplicity while improving accuracy.
Solution Approach 2:
The patent segments the complex prognosis assessment into a discrete, measurable component - the proportion of plasma cells expressing GLUT1. This segmentation allows for straightforward measurement and interpretation, avoiding the complexity of evaluating multiple interconnected biomarkers simultaneously.
3Ease of operation
If conventional prognostic factors are used, then assessment remains simple, but response to therapy prediction is insufficient
Solution Approach 1:
The patent introduces GLUT1 expression as a feedback mechanism that provides reliable information about therapy response potential. By measuring GLUT1 expression levels, clinicians can predict which patients will respond best to specific therapies, enabling more accurate treatment selection while maintaining operational simplicity.
Solution Approach 2:
The patent performs preliminary assessment of GLUT1 expression before treatment initiation, allowing prediction of therapy response in advance. This preliminary action enables clinicians to select appropriate treatments based on pre-treatment biomarker data, improving reliability without complicating the overall assessment process.
Data Source
Figure 1A
Figure 1B
Figure 2~3A
AI summary
The present invention relates to the use of the proportion of plasma cells, lymphocytes or blasts expressing GLUT1 among total plasma cells, lymphocytes or blasts in a method for stratifying prognosis of subjects suffering from a hematologic disorder, and in a method for determining whether a subject suffering from a hematologic disorder will achieve or is achieving a response with a modulator of the BCL-2 family proteins. The present invention also relates to a kit for detecting GLUT1, and optionally ASCT2, for implementing one of these methods.